The absence of a similar correlation in our study may suggest that HER2-mediated metabolic reprogramming in urothelial carcinoma operates through mechanisms distinct from those involved in triglyceride-glucose metabolism. This evidence concerns the gene ERBB2 and urothelial carcinoma.